NEWSWORTHY
Japan drugmaker Takeda mulls sale of $3 billion in emerging-market assets
Takeda Pharmaceutical Co. is considering a sale of some emerging-market drugs as it expands a push to cut debt after buying Shire PLC for $62 billion, according to sources. The company is working with Bank of America Corp. to gauge potential buyer interest in emerging-market ...
Takeda's CEO says it needs to sell assets quickly to cut debt
The sooner, the better. That's Christophe Weber's time frame for shedding assets as Takeda Pharmaceutical Co. tries to reduce a heavy debt load after completing its $62 billion takeover of Shire PLC. The company has laid out a scenario of a potential $10 billion in ...
Takeda completes buyout of Shire to become top 10 global pharmaceutical firm
Takeda Pharmaceutical Co. said Tuesday it has completed the acquisition of Irish drugmaker Shire PLC and made it a wholly owned subsidiary, becoming a global top 10 pharmaceutical company in terms of sales. The ¥6.2 trillion ($57 billion) takeover of Shire made it the biggest-ever ...
After Shire acquisition, Japanese drugmaker Takeda expects annual sales to double
Takeda Pharmaceutical Co. said Monday it expects its annual consolidated sales to nearly double to $31.3 billion after acquiring Irish drugmaker Shire PLC, a move that will make it a global top 10 company in the industry. The company also said it will issue approximately ...
Takeda downgrade looms after shareholders approve Shire deal
Takeda Pharmaceutical Co. shareholders' approval of the $62 billion (about ¥7 trillion) acquisition of Shire PLC is good news for its bosses' ambitions to build a global drug giant — but bad news for its credit ratings. The backing of what will be the largest-ever ...
With EU approval secured, Takeda clears last regulatory hurdle for $62 billion Shire purchase
Takeda Pharmaceutical Co. has won European Union approval for its takeover of Shire PLC, clearing the last major regulatory hurdle for the $62 billion acquisition and paving the way to a shareholder vote. While the acquisition sailed smoothly through the regulatory process, getting approval from ...
Takeda bets on China for global growth, seeing the country as 'on a par' with the U.S. and Europe
Takeda Pharmaceutical Co. sees China becoming a "core country" for its global growth strategy, and is optimistic its $62 billion (¥6.94 trillion) acquisition of Shire PLC will win approval by the country's regulators. Takeda is preparing to begin selling seven new drugs in China in ...
Takeda considers selling Osaka headquarters to fund Shire purchase
Takeda Pharmaceutical Co. is considering selling its symbolic Osaka headquarters building to help finance its £46 billion ($60 billion) deal to acquire Irish drugmaker Shire Plc., sources close to the matter said Friday. The building, located in the Doshomachi district in the city of Osaka, ...
Foreign mega-deals challenged by Fujifilm and Takeda shareholders
Fujifilm Holdings Corp. President Kenji Sukeno told shareholders on Thursday that the company will continue to pursue a merger with Xerox Corp. despite the U.S. printer and copier-maker's decision to terminate the deal. "It is the best option for Fuji Xerox and Xerox. I will ...
Challenges await Takeda after $62 billion Shire victory
Takeda Pharmaceutical Co.'s Chief Executive Officer Christophe Weber navigated rebuffs, critics and a plunging stock price to win a $62 billion (¥6.8 trillion) deal to acquire larger rival Shire Plc. Integrating the Japanese drugmaker — which began by selling herbal therapies 237 years ago — ...
Shire bid marks Takeda's latest and biggest push for global status
Takeda Pharmaceutical Co. Ltd..'s $64 billion bid for London-listed rare-disease specialist Shire PLC bolsters its credentials as Japan's most outward-facing drugs firm, a mold-breaking image that has been more than a decade in the making. Under CEO Christophe Weber and his predecessor, Yasuchika Hasegawa, Takeda ...
